NCT06743295 AI Noise Reduction in Phonak Hearing Aids
| NCT ID | NCT06743295 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Hearing Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-04-24 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-04-24 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if artificial intelligence- based noise reduction can offer objective improvement in hearing and speech perception for hearing impaired patients.
Eligibility Criteria
Inclusion Criteria: * Patients with hearing impairment not using hearing aids * Individuals with hearing impairment currently using hearing aids * Cochlear implant patients with a single-sided implant (using a hearing aid in the opposite ear)
Contact & Investigator
Aniket Saoji, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06743295 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Hearing Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06743295 currently recruiting?
Yes, NCT06743295 is actively recruiting participants. Contact the research team at tombers.nicole@mayo.edu for enrollment information.
Where is the NCT06743295 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06743295 clinical trial?
NCT06743295 is sponsored by Mayo Clinic. The principal investigator is Aniket Saoji, PhD at Mayo Clinic. The trial plans to enroll 500 participants.